Systematic evidence review on radiosensitizers and the abscopal effects of radiotherapy.

Authors

Amr Ali Mohamed Abdelgawwad El-Sehrawy, Dhuha Mahdi Oudah, Mirza R Baig, R Roopashree, Irwanjot Kaur, Ozodbek Nematov, Ibrokhim Sapaev, Vimal Arora, Aseel Smerat, Satya Sundar Gajendra Mohapatra

Published in

International journal of radiation biology. Pages 1-20. Aug 07, 2026. Epub Aug 07, 2026.

Abstract

The abscopal effect, defined as regression of non-irradiated tumors following localized radiotherapy (RT), is increasingly recognized as an immune-mediated phenomenon. Radiosensitizers may enhance this effect by amplifying radiation-induced immunogenicity and systemic anti-tumor immunity.
A systematic literature search for studies within PubMed/MEDLINE, Scopus, and Web of Science, covering a period from January 2015 to April 2026, was conducted. Studies eligible for inclusion were those that examined RT combined with radiosensitizing approaches and documented abscopal responses or outcomes relating to systemic anti-tumor immunity.
Thirty-one preclinical studies met the inclusion criteria. Most radiosensitizers enhanced RT efficacy through increased DNA damage, reactive oxygen species (ROS) generation, hypoxia modulation, activation of the cGAS-STING pathway, and induction of immunogenic cell death (ICD). Enhanced dendritic cell maturation, increased CD8+ T-cell infiltration, elevated pro-inflammatory cytokine production, and reduction of immunosuppressive cell populations were frequently reported. Nanoparticle (NP)-based radiosensitizers and combinations with immune checkpoint inhibitors demonstrated the strongest and most consistent abscopal responses. However, several studies achieved local radiosensitization without meaningful systemic tumor regression.
To successfully achieve radio-immune abscopal effects, tumoral radiosensitivity, immune system activation and alteration of tumor microenvironment need to occur together. More translational and clinically relevant research should generate systematic and robust evidence of treatment sequencing in different experimental frameworks and to determine durable predictive biomarkers for systemic response.

PMID:
42565751
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.